Incyte | INCY - Ordinary Share Capital


Incyte reported $200.98M in Ordinary Share Capital for its fiscal quarter ending in June of 2026.





Ordinary Share Capital Change Date
Acadia Pharmaceuticals USD 171.09M 1.9M Mar/2026
Agenus USD 38.52M 3.2M Mar/2026
Agios Pharmaceuticals USD 59.34M 892K Mar/2026
Alnylam Pharmaceuticals USD 133.73M 290K Jun/2026
Amgen USD 541M 1000K Jun/2026
BioCryst Pharmaceuticals USD 255.26M 42.2M Jun/2026
Biogen USD 146.7M 200K Sep/2025
BioMarin Pharmaceutical USD 193.54M 267K Jun/2026
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Eli Lilly USD 943.5M 3.33M Mar/2026
Exelixis USD 248.88M 4.82M Jun/2026
Gilead Sciences USD 1.24B 1000K Jun/2026
Incyte USD 200.98M 1.03M Jun/2026
Ionis Pharmaceuticals USD 165.64M 265K Jun/2026
MacroGenics USD 63.56M 241K Mar/2026
Merck USD 2.47B 4.93M Mar/2026
Moderna USD 391M 2M Sep/2025
Nektar Therapeutics USD 29.47M 9.09M Mar/2026
Neurocrine Biosciences USD 100.55M 50K Jun/2026
Novartis USD 1.9B 7.38M Jun/2026
Novartis USD 1.91B 60K Mar/2026
Pfizer USD 5.7B 0 Jun/2026
PTC Therapeutics USD 82.88M 1.41M Mar/2026
Puma Biotechnology USD 5K 0 Jun/2024
Regeneron Pharmaceuticals USD 105M 300K Mar/2026
Sarepta Therapeutics USD 105.62M 53K Jun/2026
Ultragenyx Pharmaceutical USD 98.3M 1.7M Mar/2026
Vertex Pharmaceuticals USD 253.3M 900K Jun/2026